Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Conatus Pharmaceuticals Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the study
Subjects with a clinical, radiological and/or histological diagnosis of cirrhosis
Subjects having not required hospital admission within 4 weeks of screening for a complication of cirrhosis
Subjects with an acute deterioration of liver function
Subjects who meet one of the following criteria:
1. Subjects with renal failure (defined as creatinine ≥ 2.0 to ≤ 3.4 mg/dL)
2. Subjects with other single organ failure with i. Renal impairment (defined as an increase in creatinine of \> 0.3 mg/dL from either an established prior Baseline level or if applicable, upon admission to hospital if prior level is unavailable; for inclusion, the creatinine level must be raised above normal levels), and/or ii. Hepatic encephalopathy grade I or II
3. Subjects with two organ failures
If a subject received steroids for alcohol-induced acute liver failure, he/she must be unresponsive to steroid therapy. Responsiveness is based on investigator discretion.
Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from screening to one month after the last dose of study drug
You may not be if
Known infection with HIV
Subjects with cirrhosis who develop decompensation at any time in the postoperative period following partial hepatectomy
Subjects with evidence of uncontrolled infection defined as persistent bacterial culture positivity despite adequate antibiotic therapy
Subjects with clinical evidence of disseminated intravascular coagulation
Subjects with chronic and/or pre-existing kidney disease defined as eGFR (estimated glomerular filtration rate) of less than 30 mL/min for 3 months or longer
Subjects who are hypotensive (defined as mean arterial pressure \<70 mmHg) or require the use of inotropic support
Subjects with evidence of significant and/or uncontrolled bleeding
Subjects requiring mechanical ventilation
Subjects with active or history of malignancies other than hepatocellular carcinoma (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years
Subjects previously exposed to IDN-6556
History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of \> 480 milliseconds (msec)
Clareo Health | Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
